Omnicare — Q1 2012 Earnings Presentation
18 slides from Omnicare's earnings presentation, Apr 26, 2012
Slide 1: First Quarter 2012 Financial Results Supplemental Slides
Slide 2: Forward-Looking Statements
Forward-Look Statements Certain of listed within statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-| kg i but are not tite to, i belief or fion. Such fe it uncertainties, ts, i iffer materially from those stated. The most significant of it bed in th
Slide 3: Table of Contents
Table of Contents First Quarter 2012 Highlights. Operating Metrics — Script Data... Operating Metrics — Long-Term Care Bed Data Adjusted Operating Income by Segment......... Adjusted Gross Profit & Operating Income. Adjusted Net Income & Cash-based EPS. . Cash Flows. Cash Deployment.. Capital Struct
Slide 4: First Quarter 2012 Highlights
First Quarter 2012 Highlights Gross profit increased 9.9% year-over-year to $368.1M on 4.4% sales increase Adjusted EBITDA") increased 16.0% year-over-year to $169.7M Adjusted Cash-Based EPS") of $0.81; 17.4% increase over $0.69 in 1Q11 Long-Term Care Group first-quarter performance: — Utilization u
Slide 5: Operating Metrics - Script Data
Operating Metrics Script Data (In thousands, except %s) Long-Term Care Group Scripts: Generic scripts dispensed Branded scripts dispensed Over-the-counter scripts dispensed “) Total LTC Group scripts Specialty Care Group Scripts Total scripts dispensed Generic dispensing rate ®! Sequential 1Q 2012 2
Slide 6: Operating Metrics - Long-Term Care Bed Data
Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 1Q2012_ _4Q2011_ (Decrease) _1Q2011_ (Decrease) Beds served: Beginning of period - LTC Beds 1,010 1,008 2 1,023 (14) Net change in beds served 24 2 (25) ) (15) End of period - LTC Beds 986 1,010 (24)
Slide 7: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment “) Sequential Prior Year Increase / Increase / In millions, except %s 1Q2012_ _4Q.2011__ (Decrease) 1Q 2011 (Decrease) ‘Long-Term Care Group Net sales $ 1296.3 $ 1,277.4 1.5% $ 1,200.1 0.5% Adjusted operating income) 154.2 146.3 5.4% 130.4 18.3% Rate 11.90% 11.45
Slide 8: Adjusted Gross Profit & Operating Income
Adjusted Gross Profit & Operating Income ()@) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 102012 _4Q2011_ (Decrease) _1@2011__(Decrease) Net sales $ 1,593.1 $ 1,557.1 2.3% $ 1,525.6 4.4% Cost of sales 1,225.0 1,197.4 2.3% 1,190.6 2.9% Gross profit $ 3681 $ 3
Slide 9: Adjusted Net Income & Cash-based EPS
Adjusted Net Income & Cash-based EPS")() Sequential Prior Year Increase / Increase / In millions, except per share data and %s 1Q 2012 402011 (Decrease) 1@ 2011 (Decrease) iu ing income 143.6 (134.4 120: 19.4% Adjusted investment income 0. 0. 0.3 (100.0%) Adjusted interest (expense) (24.5) (25.6) (4
Slide 10: Cash Flows
Cash Flows (1) Sequential Prior Year Increase / Increase / In millions, except %s 12012 402011 (Decrease) _1@2011 (Decrease) Net income $ 55.7 § 31.2 78.5% $ 29.3 (90.1%) Loss from discontinued operations - (100.0%) 19.9 (100.0%) Adjustments to reconcile net income to net cash flows from operating a
Slide 11: Cash Deployment
Cash Deployment In mins, except %s 1 2012 Net cash flows from operating activities of continuing operations (reported) $ 100.4 Capital expenditures 20.2 Acquisitions 06 Net debt and long term borrowings repayment "? 66 Capital returned: Dividends paid $ 78 Share repurch ase 223 Total capital retur 3
Slide 12: Capital Structure
Capital Structure Major Debt Maturity Schedule™)2) (in $ millions) a a As of 12/31/09 | wAsof 412 2010 2015 2020 2025 2030 2035 2040 ns shown ae exc Onna 20212, Onn secret 258 OM in 3.75% Stak Cone r Sus Ns ue 2012 The ancaces cased on 9 212,
Slide 13: 2012 Guidance
2012 Guidance Po Previous Guidance “) | Current Guidance @ $6.1B to $6.2B $6.1B to $6.2B > Revenue®) 2 eras Diluted Cash-Based $3.10 to $3.20 $3.10 to $3.20 $400M to $500M * Cash Flow from Operations $400M to $500M
Slide 14: Longer-Term Targets
Longer-Term Targets “) a + Adjusted Diluted EPS (old methodology) Wee Paes + Cash Flow from Operations $400-$500 million annually + Capital Returned to Shareholders Approximately 25% per year?) Focus on continued debt reduction, management of maturity schedules * Capital Structure
Slide 15: Appendix
Slide 16: Working Capital Management
Working Capital Management Five Quarter Trend 40 78 299 204 30 a 69 FO —$—<—<— om” ay — 274 uD 614 = 9.9 58.2 10 — 37 55.7 556 ° st 1a11 2a11 3011 4qi1 1012
Slide 17: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations():(2) 1Q 2012 Avalide Avapro Boniva Geodon Lexapro Seroquel 2Q-4Q 2012 Provigil Stalevo Actos Comtan Diovan Fosrenol Lidoderm Plavix Revatio Singulair Xopenex FY 2013 Aciphex Asacol Cymbalta Fragmin Humalog Lovaza Lupron Depot Niaspan Renagel Travatan Tricor
Slide 18: Slide 18